

Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents

Humberto Colmenarez¹, MD; Cristina Fernández², MD, PhD; Javier Escaned^{3*}, MD, PhD

1. Centro Cardiovascular Regional Ascardio, Barquisimeto, Venezuela; 2. Research Unit, Hospital Clinico San Carlos, Madrid, Spain; 3. Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain

KEYWORDS

- drug-eluting stents
- meta-analysis
- outcomes

Abstract

Aims: To establish whether technological improvements in drug-eluting stent (DES) technology introduced in second-generation (G2) DES have contributed to improving patient-focused outcomes.

Methods and results: We performed a systematic review of randomised clinical trials (RCT) comparing first-generation (G1) and G2 DES with a >9-month clinical follow-up. The primary endpoint for efficacy was ischaemia-driven target lesion revascularisation (ID-TLR); safety endpoints were all-cause death, myocardial infarction (MI) and stent thrombosis (ST). Sixteen RCTs involving 25,427 patients met eligibility criteria (17 comparisons). In these trials, paclitaxel (PES) and sirolimus (SES) were compared with everolimus (EES), zotarolimus (ZES) or biolimus A9 (BES) DES. G2 varied in metal alloy, strut thickness and type of drug-eluting matrix. Overall, G2 DES were associated with a 26% relative risk reduction (RRR) of MI (relative risk [RR]=0.74, 95% CI: 0.61-0.90, p=0.003) and ST (RR=0.70, 95% CI: 0.55-0.89, p=0.004), while no significant benefit was observed for ID-TLR and death. Use of 2G DES was associated with a significant reduction in the risk of ID-TLR (RR=0.66, 95% CI: 0.51-0.85, p=0.002), MI (RR=0.60, 95% CI: 0.49-0.72, p<0.001) and ST (RR=0.41, 95% CI: 0.26-0.65, p=0.001) when compared with PES. Strut thickness ≤91 µm in G2 DES was associated with a significantly lower risk of MI (RR=0.54, 95% CI: 0.51-0.86, p=0.002).

Conclusions: The introduction of thinner stent struts and other technological improvements made in G2 DES technology have translated into better patient outcomes. Overall, the net benefit of G2 DES over G1 DES is expressed in terms of ID-TLR and ST risk reduction but it could be masked by heterogeneities in the use of G1 comparators and the use of non-inferiority study designs in RCTs.

*Corresponding author: Instituto Cardiovascular, Hospital Clínico San Carlos, 28040 Madrid, Spain.

E-mail: escaned@secardiologia.es

Abbreviations

BES	biolimus-eluting stent
BMS	bare metal stent
CAD	coronary artery disease
DES	drug-eluting stent
EES	everolimus-eluting stent
G1 DES	first-generation drug-eluting stent
G2 DES	second-generation drug-eluting stent
ID-TLR	ischaemia-driven target lesion revascularisation
MI	myocardial infarction
NNT	number needed to treat
PES	paclitaxel-eluting stent
RCT	randomised clinical trial
RR	relative risk
RRR	relative risk reduction
SES	sirolimus-eluting stent
ST	stent thrombosis
ZES	zotarolimus-eluting stent

Introduction

Drug-eluting stents (DES) have contributed to the widespread use of percutaneous coronary revascularisation, following the demonstration that they significantly reduce restenosis rates¹. Most of the available information on DES efficacy and safety stems from randomised clinical trials using the sirolimus-eluting stent CYPHER[®] (Cordis, Johnson & Johnson, Warren, NJ, USA) and the paclitaxel-eluting stent TAXUS[™] Express2[™] (Boston Scientific, Natick, MA, USA)². The enthusiasm generated by these first-generation (G1) DES has been tempered by growing evidence revealing that DES would not abolish restenosis, but rather would reduce its occurrence¹. Furthermore, the demonstration of a higher prevalence of late and very late stent thrombosis in DES, compared with BMS, became a new matter of concern for interventionalists³. With the aim of overcoming these problems, newer DES designs introduced changes both in the structural characteristics of the stent platform and in the antiproliferative cover (eluting polymer and drug). Since second-generation (G2) DES have been tested individually against a pre-existing G1 DES in non-inferiority trials for their approval by regulatory agencies, the overall clinical benefit of G2 DES has not been explored.

With this aim, we performed a systematic review and meta-analysis of the available clinical trials comparing G1 and G2 DES, paying attention to the clinical benefit and to the effect of individual modifications made in DES technology.

Methods

The study was performed in compliance with the Cochrane Handbook for Systematic Reviews of Interventions and the recommendations set forth by the Quality of Reporting of Meta-Analysis (QUORUM)^{4,5}. First-generation DES were the sirolimus-eluting stent CYPHER[®] and the paclitaxel-eluting stent TAXUS[™]. Versions of the CYPHER (CYPHER[®] and CYPHER SELECT[®]) and TAXUS (TAXUS[™] Express2[™] and TAXUS[®] Liberté[®]) were included as G1 DES on the grounds that no significant changes in

alloy, strut thickness, eluting polymer or drug were introduced. Second-generation DES were defined as those introduced later with modifications in antiproliferative drug, eluting polymer or stent platform.

SEARCH STRATEGY

An electronic search for trials comparing G1 and G2 DES was performed by two independent investigators in TripDatabase, PubMed, Cochrane Central Register of Controlled Trials, abstract databases from relevant scientific congresses (American College of Cardiology, American Heart Association, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics and EuroPCR) and internet-based sources of information on cardiology (cardiosource.com, escardio.org, tctmd.com, the heart.org and ctronline.com). The search period was January 2003 to September 2011. Appropriate medical subjects heading (MeSH) terms and free text words including “stent”, “drug-eluting stent”, “sirolimus-eluting stent”, “paclitaxel-eluting stent”, “everolimus-eluting stent”, “biolimus-eluting stent”, “zotarolimus-eluting stent”, “coronary artery disease”, and “randomised clinical trial” were used. In addition, relevant reviews and earlier meta-analyses were also reviewed for potential studies. Principal investigators of trials were contacted whenever required to provide missing data from presentations as Late Breaking Trials in the above conferences and still in press. No language restrictions were enforced.

CRITERIA FOR STUDY SELECTION

Studies were included if they: 1) compared G1 and G2 DES using a randomised design and used ischaemia-driven target lesion revascularisation as efficacy endpoint; and 2) reported on outcomes of interest during a follow-up period ≥ 9 months. Randomised comparisons between G1 versus G2 DES exclusively addressing subgroups were excluded.

Inclusion or exclusion of studies was performed hierarchically, based on the title of the report first, followed by the abstract and then by the full text. Consulting a third investigator solved disagreement on study selection.

OUTCOME AND CLINICAL DEFINITIONS

The primary efficacy endpoint of interest was ischaemia-driven target lesion revascularisation (referred hereafter as ID-TLR), and defined as any revascularisation procedure (percutaneous or surgical) involving the target lesion owing to significant luminal renarrowing in the presence of symptoms or objective signs of ischaemia. The endpoints of all death and myocardial infarction were defined according to definitions proposed by Cutlip et al for coronary stent trials⁶. Stent thrombosis was adjudicated according to the criteria for definitive or probable stent thrombosis of the Academic Research Consortium⁶. Possible STs were not considered.

DATA ABSTRACTION

Two independent investigators using prespecified standardised forms independently extracted data. Data extracted included: trial name, publication year, sample size and characteristics, study

design, stent type characteristics, type of intervention (number of patients and lesions allocated to G1 or G2 DES), length of follow-up, presence of mandated angiographic follow-up, minimal length of dual antiplatelet therapy, outcome measures and primary end-points. In case of studies reporting results at different follow-up times, the most recent report published in a peer review was chosen. In case of incomplete or unclear data, authors were contacted. Disagreements were resolved by consensus.

QUALITY ASSESSMENT

Two authors independently assessed the methodological quality of the included trials using a method proposed by the Cochrane Handbook for Systematic Reviews of Interventions⁴. In summary, quality assessment was performed using the following criteria: 1) peer review or abstract presentation; 2) setting; 3) adequacy of the randomisation process; 4) adequacy of the allocation concealment process; 5) potential for selection bias after allocation; 6) level of masking; and 7) presence of other sources of bias. Additional details regarding quality assessment are provided in **Table 1**.

DATA ANALYSIS

Inter-observer agreement for study selection and data abstraction was performed using Cohen's weighted kappa. For each study, we calculated the summary risk ratios (RR) and their 95% confidence intervals for clinical outcomes. A random effects meta-analysis was used to estimate overall relative risks. Overall treatment effect was first calculated separately for RCTs comparing PES or SES versus

second-generation DES and then for pooled data. In addition to recent direct comparisons between SES and EES, an adjusted indirect comparison between SES and EES based on pre-existing trials using a common comparator (PES) was performed according to the method laid out by Bucher et al⁷. In our study, data for the indirect comparison were obtained from a direct meta-analysis for the risk of ID-TLR, MI and death in trials comparing PES versus EES and data from a recently published meta-analysis of trials comparing SES versus PES⁸, to investigate the clinical benefit of EES versus SES. Since strut thickness, type of platform and polymer might affect clinical outcomes, a stratified analysis adjusted for these variables was performed. We also conducted sensitivity analyses to assess the effects of selected methodological and clinical variables on ID-TLR, MI, all deaths and ST.

We assessed the results for heterogeneity by examining the forest plots and then calculating a Q statistic which we compared with a χ^2 distribution, and the I² index. The potential sources of heterogeneity were investigated by stratified and meta-regression analysis. Variables included in the model were identified by ‡ in the Tables. Influence analysis for each outcome was performed. A study was considered influential if its exclusion changed the effect estimate by at least 20. The potential publication bias was assessed using funnel plots, Begg's correlation and Egger's regression. The p-value for heterogeneity (p_{het}) was considered statistically significant when <0.10; otherwise, a p-value ≤ 0.05 was considered significant. Analyses were performed using Review Manager Version 5.1 (Cochrane Collaboration, Software Update, Oxford, UK) and EpiData version 3.1 (The EpiData Association, Odense, Denmark).

Table 1. Quality assessment of trials included.

	Peer-review/ Abstract	Setting	Adequate randomisation	Adequate concealment	Adequate masking	Selection bias	Other sources of bias
COMPARE	Pub	Single-centre	A	A	B	A	Single-centre trial
ENDEAVOR III	Pub	Multicentre	A	B	B	A	ST events by ARC criteria was performed as <i>post hoc</i> analysis
ENDEAVOR IV	Pub	Multicentre	A	B	B	A	ST events by ARC criteria was performed as <i>post hoc</i> analysis
EXCELLENT	Abs	Multicentre	B	B	C		Open-label RCT
ISAR-TEST-2	Pub	Two centres	A	A	C	A	Open-label RCT
ISAR-TEST-4	Pub	Two centres	B	B	C	A	Assessment based on conference abstract
NOBORI 1 (phase II)	Pub	Multicentre	A	A	B	A	ST events by ARC criteria was performed as <i>post hoc</i> analysis
NOBORI Japan trial	Abs	Multicentre	B	B	B	A	Assessment based on conference abstract
LEADERS	Pub	Multicentre	A	A	B	A	–
RESET	Pub	Multicentre	A	A	B	A	Open-label RCT
SPIRIT II	Pub	Multicentre	A	A	B	A	–
SPIRIT III	Pub	Multicentre	A	A	B	A	–
SPIRIT IV	Pub	Multicentre	A	A	B	A	–
SORT OUT III	Pub	Multicentre	A	A	C	A	Open-label RCT
SORT OUT IV, 2010	Abs	Multicentre	B	B	C	A	Assessment based on conference abstract. Open-label RCT
ZEST	Pub	Multicentre	A	A	B	A	–

Adequacy of the randomisation process: A. Adequate sequence generation is reported; B. Did not specify one of the adequate reported methods in (A) but mentioned randomisation method; C. Other methods of allocation that appear to be unbiased. Adequacy of the allocation concealment process: A. Adequate measures to conceal allocations; B. Unclearly concealed trials, in which the authors either did not report an allocation concealment approach at all, or reported an approach that did not fall into one of the categories in (A); C. Inadequately concealed trials, in which method of allocation was not concealed. Adequacy of masking: A. Double (or triple) blind; B. Single blind; C. Non-blind. Potential for selection bias after allocation: A. Studies where an intention to treat analysis is possible and few exclusions (with adequate reporting of these exclusions); B. Studies which reported exclusions as reported in (A), but exclusions were less than 10%; C. No reporting of exclusions; exclusions of 10% or more or wide differences in exclusions between groups. ARC: Academic Research Consortium; ST: stent thrombosis

The number needed to treat (NNT) and the number of avoided events per 1,000 treated patients were calculated as a marker of clinical relevance of using a given DES generation over the other, using Stata 12 statistical software (StataCorp LP, College Station, TX, USA).

Results

LITERATURE SEARCH

A description of the results of the RCTs search is shown as a flow chart in **Figure 1**. Our initial search yielded 152 references, of which 114 were excluded during the preliminary screening. Full texts of the remaining 38 articles were scrutinised to determine eligibility. Sixteen studies fulfilled eligibility criteria and were included for data abstraction. Six RCTs comparing PES versus second-generation DESs (ZES, EES or BES) and ten trials comparing SES versus ZES, EES or BES were found. The ZEST trial (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent versus Sirolimus-Eluting and Paclitaxel-Eluting Stent for Coronary Lesions) performed a three-arm comparison of two G1 (PES and SES) and one G2 DES (ZES)⁹. By using the ZES arm as a common comparator, data from the ZEST trial were entered in our meta-analysis as separate comparisons of ZES against PES and SES, in accordance with the recommendations proposed by the Cochrane Handbook for Systematic Reviews of Interventions⁴. The ISAR-TEST-2 included three study

arms: SES (CYPHER[®] stent), ZES and a polymer-free dual probucol-sirolimus DES¹⁰. Only data from the SES (G1 DES) and ZES (G2 DES) arms were entered in our meta-analysis. Likewise, the ISAR-TEST-4 included three treatment arms: biodegradable SES, non-erodible SES and non-erodible ESS¹¹. Only data from non-erodible SES (G1 DES) versus non-erodible EES (G2 DES) arms were entered in this analysis. Agreement between investigators regarding data search was good ($k=0.81$).

CHARACTERISTICS OF THE TRIALS INCLUDED

A total of 25,427 patients were included in the meta-analysis. More patients had been treated with G2 DES (13,653; 54%) than with G1 DES (11,774; 46%), because several studies used imbalanced randomisation^{12-15,17,21-23}. **Table 2** summarises relevant data on clinical and stent design variables for individual trials. Mean age ranged from 62 to 69 years, with the majority of patients being male. The frequency of diabetes mellitus ranged from 14 to 45% with no significant differences between compared groups except in the NOBORI trial 1 (phase 2), that included more diabetic patients in the G1 DES arm¹⁶. Follow-up ranged from nine to 60 months; the weighted mean follow-up was 21.8 months. Twelve trials had mandated angiographic follow-up, and the mean of angiographic follow-up was of 68%^{9-11,13-21}. Duration of dual antiplatelet use in all trials ranged from three to 12 months.




Figure 1. Study selection flowchart. *ZEST compared PES and SES versus ZES. BES: biolimus A9-eluting stent; EES: everolimus-eluting stent; ID-TLR: ischaemia-driven target lesion revascularization; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent; ZES zotarolimus-eluting stent

Table 2. Characteristics of the stents used in trials included.

Study	Stent platform architecture, alloy and strut thickness (µm)		Copolymer cover		Antiproliferative drug / % release kinetics (28 days)	
	DES control	DES active	DES control	DES active	DES control (µg/cm ²)	DES active (µg/cm ²)
COMPARE	TAXUS Liberté Stainless steel 316L alloy; open cell; 132 µm	XIENCE V® MULTI-LINK VISION® L-605 cobalt-chromium alloy; 81 µm	Non-erodible polymer matrix, SIBS	Fluoropolymer	Paclitaxel (100), <10%	Everolimus (100), 80%
ENDEAVOR III	Cypher® stent (Bx VELOCITY™ stent); closed cell; stainless steel 316L alloy; 140 µm	Endeavor Sprint® Cobalt-chromium alloy; open cell; 91 µm	Non-erodible biostable polymer matrix (SR) (PEVA+PBMA)	Non-erodible phosphorylcholine	Sirolimus (140), 80%	Zotarolimus (100), 15%*
ENDEAVOR IV	TAXUS Express2 SR Stainless steel 316L alloy; open cell; 132 µm	Endeavor Sprint® Cobalt-chromium alloy; open cell; 91 µm	Non-erodible polymer matrix, SIBS	Non-erodible phosphorylcholine	Paclitaxel (100), <10%	Zotarolimus (100), 15%*
EXCELLENT	Cypher® Select™; closed cell; stainless steel 316L alloy; 140 µm	XIENCE V® MULTI-LINK VISION® L-605 cobalt-chromium alloy; 81 µm	Non-erodible polymer matrix, SIBS	Fluoropolymer	Sirolimus (140), 80%	Everolimus (100), 80%
ISAR-TEST-2	Cypher® stent (Bx VELOCITY™ stent); closed cell; stainless steel 316L alloy; 140 µm	Endeavor Sprint Cobalt-chromium alloy; open cell; 91 µm	Non-erodible biostable polymer matrix (SR) (PEVA+PBMA)	Non-erodible phosphorylcholine	Sirolimus (140), 80%	Zotarolimus (100), 15%*
ISAR-TEST- 4	Cypher® stent (Bx VELOCITY™ stent); closed cell; stainless steel 316L alloy; 140 µm	XIENCE V® MULTI-LINK VISION® L-605 cobalt-chromium alloy; 81 µm	Non-erodible biostable polymer matrix (SR) (PEVA+PBMA)	Fluoropolymer	Sirolimus (140), 80%	Everolimus (100), 80%
NOBORI 1	TAXUS Express2 SR Stainless steel 316L alloy; open cell; 132 µm	Nobori™ DES; stainless steel 316L S-stent; 125 µm	Non-erodible polymer matrix, SIBS	Erodible Poly-lactic acid with abluminal coating drug	Paclitaxel (100), <10%	Biolimus A9 15.9 µg/mm, 45%
NOBORI Japan trial	TAXUS Liberté Stainless steel 316L alloy; open cell; 132 µm	Nobori™ DES; stainless steel 316L S-stent; 125 µm	Non-erodible polymer matrix, SIBS	Erodible Poly-lactic acid with abluminal coating drug	Paclitaxel (100), <10%	Biolimus A9 15.9 µg/mm, 45%
LEADERS	Cypher® Select™; closed cell; stainless steel 316L alloy; 140 µm	BioMATRIX™ Flex; stainless steel 316L S-stent; 112 µm	Non-erodible polymer matrix, SIBS	Erodible Poly-lactic acid with abluminal coating drug	Sirolimus (140), 80%	Biolimus A9 15.9 µg/mm, 45%
RESET	Cypher® Select™; closed cell; stainless steel 316L alloy; 140 µm	XIENCE V® MULTI-LINK VISION® L-605 cobalt-chromium alloy; 0,0032"	Non-erodible polymer matrix, SIBS	Fluoropolymer	Sirolimus (140), 80%	Everolimus (100), 80%
SPIRIT II	TAXUS Express2 SR Stainless steel 316L alloy; open cell; 132 µm	XIENCE V® MULTI-LINK VISION® L-605 cobalt-chromium alloy; 81 µm	Non-erodible polymer matrix, SIBS	Fluoropolymer	Paclitaxel (100), <10%	Everolimus (100), 80%
SPIRIT III	TAXUS Express2 SR Stainless steel 316L alloy; open cell; 132 µm	XIENCE V®MULTI-LINK VISION® L-605 cobalt-chromium alloy; 81 µm	Non-erodible polymer matrix, SIBS	Fluoropolymer	Paclitaxel (100), <10%	Everolimus (100), 80%
SPIRIT IV	TAXUS Express2 SR Stainless steel 316L alloy; open cell; 132 µm	XIENCE V® MULTI-LINK VISION® L-605 cobalt-chromium alloy; 81 µm	Non-erodible polymer matrix, SIBS	Fluoropolymer	Paclitaxel (100), <10%	Everolimus (100), 80%
SORT OUT III	Cypher® stent (Bx VELOCITY™ stent); closed cell; stainless steel 316L alloy; 140 µm	Endeavor Sprint® Cobalt-chromium alloy; open cell; 91 µm	Non-erodible biostable polymer matrix (SR) (PEVA+PBMA)	Non-erodible phosphorylcholine	Sirolimus (140), 80%	Zotarolimus (100), 15%*
SORT OUT IV	Cypher® Select™; closed cell; stainless steel 316L alloy; 140 µm	XIENCE V® MULTI-LINK VISION L-605 cobalt-chromium alloy; 81 µm	Non-erodible polymer matrix, SIBS	Fluoropolymer	Sirolimus (140), 80%	Everolimus (100), 80%
ZEST †	Cypher® stent (Bx VELOCITY™ stent); closed cell; stainless steel 316L alloy; 140 µm	Endeavor Sprint® Cobalt-chromium alloy; open cell; 91 µm	Non-erodible biostable polymer matrix (SR) (PEVA+PBMA)	Non-erodible phosphorylcholine	Sirolimus (140), 80%	Zotarolimus (10), *15%

* 100% is delivered in 15 days. †ZEST trial included three treatment arms: ZES vs. SES and ZES vs. PES. SR: slow release; PEVA+PBMA: Polyethylene Vinyl Acetate (PEVA) + Poly n-butyl Methacrylate (PBMA); SIBS: Styrene-Isobutylene-Styrene

The following RCTs followed a non-inferiority design: COMPARE, ENDEAVOR III, ENDEAVOR IV, EXCELLENT, ISAR-TEST-2, ISAR-TEST-4, NOBORI Japan, RESET, SPIRIT III and SORT OUT IV^{10-15,17,19,21,24}. A non-inferiority/superiority design was followed in the NOBORI, LEADERS, SPIRIT II and SPIRIT IV RCTs^{17,18,20,22}. Finally, a superiority approach was followed in the SORT OUT III only²³. The ZEST trial compared a G2 DES (ZES) versus a G1 DES (SES) on a superiority design and a G1 DES (PES) on a non-inferiority design⁹.

Four trials (ENDEAVOR III, EXCELLENT, NOBORI I [phase 2], SPIRIT II) used angiographic primary endpoints (restenosis and late lumen loss)^{13,15,16,20}, while the remaining trials used combined clinical endpoints as primary endpoints^{9-12,14,17-19,21-24}. Four trials followed an all-comers design^{9,13,19,24}. With the exception of the COMPARE trial, all studies were conducted in two or more centres.

Table 3 summarises the structural characteristics of DES platforms used in the included RCTs. Some of the structural changes

Table 3. Characteristics of trials and patients included.

Trial name, year, (No. of reference)	Patients	Age (years), male (%)	DM (%)	Design	Patients' profile and lesion types	Interventions	Primary and secondary endpoints	Clinical FU (months), angiographic FU (yes or no)	Minimal length of DAT (months)
COMPARE, 2010 ⁹	N: 1,800 DES (a): 897 DES (c): 903	DES (a): 69 DES (c): 72	DES (a): 17 DES (c): 19	Single-blind non-inferiority RCT (2:1)	All patients eligible for PCI "all-comers"	PES vs. ESS	MACE (death, MI and TVR) / MACE (cardiac death, MI, ID-TLR) and ST	24, no	12
ENDEAVOR III, 2011 ¹⁰	N: 436 DES (a): 323 DES (c): 113	DES (a): 61, 71 DES (c): 62, 74	DES (a): 30 DES (c): 29	Single-blind non-inferiority RCT (3:1)	Patients with symptomatic CAD due to de novo stenotic lesion (ϕ = 2.5 to 3.5 mm and length \geq 14 mm and \leq 27 mm)	SES vs. ZES	LL/ MACE (all-cause death, MI and ID-TLR): individual components of MACE; ID-TVR and ST	60, yes	3
ENDEAVOR IV, 2009 ¹¹	N: 1,548 DES (a): 774 DES (c): 774	DES (a): 64, 67 DES (c): 64, 69	DES (a): 31 DES (c): 31	Single-blind non-inferiority RCT (3:1)	Patients with symptomatic CAD due to de novo stenotic lesion (ϕ = 2.5 to 3.5 mm and length \geq 14 mm and \leq 27 mm)	SES vs. ZES	TVF (cardiac death, MI and ID-TLR) / % DS; MACE (all-cause death, MI and TVR); TVR, ID-TLR and ST	24, yes	\geq 6
EXCELLENT, 2010 ¹²	N: 1,548 DES (a): 1,079 DES (c): 364	DES (a): 63, 65 DES (c): 63, 63	DES (a): 37 DES (c): 40	Open-label non-inferiority RCT (3:1)	Patients with stable CAD and ischaemic symptoms or evidence of myocardial ischaemia due to coronary stenosis \geq 50% (ϕ = 2.25 to 4.25 mm)	SES vs. EES	LL/ MACE (all-cause death, MI and ID-TLR): individual components of MACE; ID-TVR and ST	12, yes	6-12
ISAR-TEST- 2, 2010 ¹³	N: 570 DES (a): 335 DES (c): 335	DES (a): 67, 77 DES (c):67, 77	DES (a): 26 DES (c): 27	Open-label non-inferiority RCT (1:1)	Patients with stable CAD and ischaemic symptoms or evidence of myocardial ischaemia due to coronary stenosis \geq 50%	SES vs. ZES	MACE (all-cause death, MI and ID-TVR) / combined death/MI; ID-TLR; ST; LL, RR	24, yes	12
ISAR-TEST-4, 2011 ¹⁴	N: 1,304 DES (a): 652 DES (c): 652	DES (a): 67, 78 DES (c): 67, 76	DES (a): 28 DES (c): 30	Open-label non-inferiority RCT (1:1:1)	Patients with stable CAD and ischaemic symptoms or ACS in presence of \geq 50% <i>de novo</i> stenosis in native coronary vessels	SES vs. EES	Composite of cardiac death, target vessel MI or ID-TLR. 2nd endpoints were death, ST, RR and LL	36, yes	6
NOBORI 1, 2009 ¹⁵	N: 243 DES (a): 153 DES (c): 90	DES(a): 63, 75 DES (c): 63, 69	DES (a): 16 DES (c): 28*	Single-blind non-inferiority/superiority RCT (3:1)	Patients with stable or unstable angina and/or inducible ischaemia due to coronary stenosis \geq 50%. (ϕ =2.5 to 3.5 mm and length \geq 5 mm and \leq 25 mm)	PES vs. BES	LL/ MACE (cardiac death, MI, TVR and emergent CABG); TVF; ID-TLR; ST and RR	9, yes	6
NOBORI Japan trial, 2010 ¹⁶	N: 326 DES (a): 194 DES (c): 132	DES (a): 69, 78 DES (c): 69, 76	DES (a): 39 DES (c): 39	Single-blind non-inferiority RCT (3:2)	Patients with stable or unstable angina and/or inducible ischaemia due to de novo lesions $>$ 50% (ϕ =2.5 to 3.5 mm and length \leq 30 mm)	SES vs. BES	TVF (TVR, cardiac death, MI)/LL, RR, ID-TLR, cardiac death, MI, ST	24, yes	6
LEADERS, 2011 ¹⁷	N: 1,721 DES (a): 857 DES (c): 850	DES (a): 65, 75 DES (c): 65, 75	DES (a): 26 DES (c): 23	Single-blind non-inferiority/superiority RCT (1:1)	Patients with CAD or ACS (STEMI or non-STEMI) with at least 1 lesion $>$ 50 % (ϕ =2.25 to 3.5 mm)	SES vs. BES	MACE (cardiac death, MI and ID-TVR) / ID-TLR and TVR; TVF; RR and LL.	24, yes	12
RESET ¹⁸	N: 3,197 DES (a): 1,597 DES (c): 1,600	DES (a): 65, 75 DES (c): 65, 75	DES (a): 45 DES (c): 45	Open-label non-inferiority/ RCT (1:1)	All patients eligible for PCI "all-comers".	SES vs. EES	Any TLR and death or MI /ID-TLR	12, yes	12
SPIRIT II, 2011 ¹⁹	N: 300 DES (a): 223 DES (c): 77	DES (a): 62, 71 DES (c): 62, 79	DES (a): 23 DES (c): 24	Single-blind non-inferiority/superiority RCT (3:1)	Patients with myocardial ischaemia. Treatment of up to two de novo native coronary artery lesions was permitted (ϕ = 2.5 to 4.0 mm and length $<$ 28 mm)	PES vs. EES	LL / MACE (cardiac death, MI and TVR) , ID-TLR and ST	48, yes	6
SPIRIT III, 2011 ²⁰	N: 1,002 DES (a): 669 DES (c): 333	DES (a): 63, 76 DES (c): 63, 74	DES (a): 30 DES (c): 28	Single-blind, non-inferiority RCT (2:1)	Patients with stable or unstable angina and/or inducible ischaemia. Treatment of up to two de novo native coronary artery lesions was permitted (ϕ = 2.75 to 3.75 mm and length $<$ 28 mm)	PES vs. ESS	TVF (cardiac death, MI or ID- TVR) / MACE (cardiac death, MI or ID- TLR)/ ST	36, yes	6

Table 3. Characteristics of trials and patients included. (contd)

Trial name, year (No. of reference)	Patients	Age (years), male (%)	DM (%)	Design	Patients' profile and lesion types	Interventions	Primary and secondary endpoints	Clinical FU (months), angiographic FU (yes or no)	Minimal length of DAT (months)
SPIRIT IV, 2011 ²¹	N: 3,687 DES (a): 2,458 DES (c): 1,229	DES (a): 63, 77 DES (c): 63, 76	DES (a): 32 DES (c): 33	Single-blind, non-inferiority / superiority RCT (2:1)	Patients with stable or unstable angina or inducible ischaemia. Maximum 3 <i>de novo</i> native coronary artery lesions was permitted ($\phi \geq 2.5$ to ≤ 3.75 mm and length ≤ 28 mm)	PES vs. ESS	TLF (cardiac death, target vessel MI or ID-TVR) / ID-TLF (composite of cardiac death and TV-MI); ID-TLR, MACE, TVF and ST	24, no	12
SORT OUT III 2010 ²²	N: 2,332 DES (a): 1,170 DES (c): 1,162	DES (a): 64, 73 DES (c): 64, 74	DES (a): 15 DES (c): 14	Open-label superiority RCT (1:1)	Patients with CAD or ACS (STEMI or non-STEMI) with at least 1 lesion >50%.	SES vs. ZES	All-cause death, cardiac mortality, MI and ST/ ID-TLR and RR	9, no	12
SORT OUT IV 2011 ²³	N: 2,774 DES (a): 1,390 DES (c): 1,384	DES (a): 64, 76 DES (c): 64, 75	DES (a): 14 DES (c): 14	Open-label, non-inferiority RCT (1:1)	All patients eligible for PCI "all-comers".	SES vs. EEV	Composite endpoint (cardiac death, MI, ST or TVR). ID-TLR as 2nd endpoint	9, no	12
ZEST †, 2010 ²⁴	N: 1,764 DES (a): 884 DES (c1): 880	DES (a): 62, 66 DES (c): 62, 66	DES (a): 30 DES (c): 28	Single-blind non-inferiority (ZES vs. SES) and superiority (ZES vs. PES) RCT (1:1:1)	Patients with stable angina, silent ischaemia or ACS (non-STEMI or STEMI) with at least 1 lesion >50%	SES or PES vs. ZES	MACE (all-cause death, MI and ID-TVR)/ composite of death and MI; ID-TLR; ID-TVR; ST; RR/LL	12, yes	12

DES ac: drug-eluting stent active comparator; DES ae (G1 DES): drug-eluting stent active experimental (G2 DES); MACE: major cardiovascular events; MI: myocardial infarction; TVR: target vessel revascularisation; TLR: target lesion revascularisation; ID-TLR: ischaemia-driven target lesion revascularisation; ID-TVR: ischaemia-driven target vessel revascularisation; CAD: coronary artery disease; LL: late loss; RR: restenosis rate; ST: stent thrombosis; TVF: target vessel failure; TLF: target lesion failure; DAT: dual antiplatelet therapy. COMPARE: Second-Generation Everolimus-Eluting and Paclitaxel-Eluting Stents in Real-Life Practice; ENDEAVOR III: A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions; ENDEAVOR IV: (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial; EXCELLENT: Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stenting; ISAR-TEST-2: Intracoronary Stenting and Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators; ISAR-TEST-4: Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators; NOBORI 1: Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in patients With stenosis in Native Coronary Arteries; RESET: Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents. 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial; SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System; SPIRIT III: Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial; SPIRIT IV: Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System; SORT OUT III: Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Coronary Artery Disease; SORT OUT IV: Scandinavian Organization for Randomized Trials with Clinical Outcome SORT OUT IV investigators; ZEST: Comparison of Sirolimus and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice; LEADERS: Limus Eluted from A Durable versus Erodable Stent coating

introduced in G2 DES were the use of cobalt-chromium alloys, thinner strut thickness (≤ 95 microns) and erodible or biodegradable eluting polymers.

Direct comparisons between COMPARE, SPIRIT II, SPIRIT III and SPIRIT IV trials were performed to estimate the clinical benefit of EES over PES^{12,20-22}. Likewise, data reported in a meta-analysis were used to estimate the performance of SES versus PES⁸. Then, adjusted indirect comparisons using a methodology proposed by Bucher were performed⁷.

RISK OF BIAS OF INCLUDED STUDIES

The majority of trials were published as peer-reviewed publications. The limited information on trial methodology in conference abstracts and presentations affected our ability to assess the quality of three trials^{15,17,24}. The results of the quality assessment are presented in **Table 1**. Overall, no trials achieved "A" across all elements of the quality assessment. With regard to the adequacy of the randomisation process and concealment, a rating of "A" was given

to 11 of the 16 trials^{9,10,12-14,16,18-23}. The remaining trials were all rated as "B". In relation to adequate masking, six trials were open-label and were therefore rated with a "C"^{10,11,15,19,23,24}. The remaining trials were single-blinded; therefore, they were rated as "B". The reporting of exclusions and the use of intention-to-treat analysis were very good across all trials: all were rated as "A". Stent thrombosis analyses by ARC criteria were performed *post hoc* in three trials and these were considered as a potential source of bias^{13,14,16}. An independent endpoint review committee participated in the adjudication of events across all trials.

ISCHAEMIA-DRIVEN TARGET LESION REVASCLARISATION

Figure 2 shows the forest plot of relative risk (RR) of ID-TLR in the included studies. Sixteen trials (17 comparisons) involving a total of 25,427 patients reported the incidence of ID-TLR in those allocated to G1 DES (n=11,774) or G2 DES (n=13,653) treatment. Pooled analysis revealed ID-TLR rates of 5% (1,289 events) for the overall population, 5.59% (647/11,774) for G1 and 4.70% (642/13,653) for




Figure 2. Ischaemia-driven target lesion revascularisation in first and second-generation drug-eluting stents. Forest plot illustrating the relative risk of ischaemia-driven target lesion revascularisation with first versus second-generation drug-eluting stents. Filled squares represent relative risks; square areas are proportional to the weight of individual studies; diamonds represent pooled relative risks; horizontal lines represent 95% confidence intervals.

G2 DES. No significant relative risk reduction (RRR) in ID-TLR was associated with the use of G1 or G2 DES (RR=0.91, 95% CI: 0.68-1.20, p=0.60). Significant heterogeneity was detected across studies, and meta-regression analysis identified length of follow-up (beta=-1.83, p=0.01) and stent type (beta=-0.58, p=0.05) as main determinants. Influence analysis yielded an RR range of 0.82 (95% CI: 0.62-1.11) to 0.95 (95% CI: 0.65-1.34), and exclusion of individual studies did not significantly modify the overall effect.

Separate analysis of studies comparing G2 DES with PES disclosed ID-TLR rates of 6.57% for PES (282/4,291) and 4.39% for G2 DES (247/5,614), yielding a significant RRR of 36% in favour of G2 DES (RR= 0.64, 95% CI: 0.49-0.85, p=0.002). For PES versus G2 DES comparisons, two studies reported statistically significant differences associated with G2 DES use^{12,22} while two studies favoured SES use when compared with G2 DES^{9,23} (**Figure 2**). Regarding the studies that compared G2 DES with SES, calculated ID-TLR rates were 4.62% for SES (346/7,483) and 4.83% for G2 DES (389/8,039). No significant RRR was found associated with the use of G2 DES or SES (RR=1.17, 95% CI: 0.98-1.16, p=0.43).

Adjusted indirect comparison analysis showed a significant RRR of 24% with EES use when compared with SES (RR=0.69, 95% CI: 0.56-0.85, p=0.05) (**Figure 3A**).

Stratified analysis of the included studies according to DES characteristics did not suggest that ID-TLR was influenced by stent strut thickness, erodible or non-erodible polymer (**Figure 4**).

MYOCARDIAL INFARCTION

Figure 5 shows the forest plot of the relative risks of MI in all trials included. Myocardial infarction rates were reported in 15 studies (16 comparisons, 24,193 patients). The ISAR-TEST-4 was excluded from this analysis due to MI rates not being reported¹⁰. In total, 873 events (3.60%) were reported. In the overall population, the MI rate was significantly lower in G2 (2.97%, 387/13,001) than in G1 DES (4.36%, 486/11,122), with an associated 26% RRR (RR=0.74, 95% CI: 0.61-0.90, p=0.003). The number of MI events prevented by using G2 DES in 1,000 patients was 13.6 (95% CI: 9.2-17.5) (NNT=73.3). A significant heterogeneity was documented in the overall analysis (I²= 54%, p_{het}=0.006), with length of follow-up and stent type (β=-0.63, p=0.04, β=-1.17, p=0.05, respectively) as




Figure 3. Indirect comparisons between sirolimus-eluting stents and everolimus-eluting stents based on randomised clinical trials that use paclitaxel-eluting stents as a common comparator. The Figure shows the result of adjusted indirect comparisons (lower panels) between sirolimus (SES) and everolimus (EES)-eluting stents based on trials comparing SES and paclitaxel-eluting stents (PES) and trials comparing EES and PES (upper panels). PES serve as a common comparator in these indirect comparisons. Indirect comparisons are shown for the following endpoints: A) ischaemia-driven target lesion revascularisation; B) myocardial infarction; and C) death. Black diamond represents pooled relative risks for direct comparison while red diamond shows the benefit for the adjusted indirect comparison. Horizontal lines represent 95% confidence intervals. EES: everolimus-eluting stent; PES: paclitaxel-eluting stent; RR: relative risk; SES: sirolimus-eluting stent

main determinants. Influence analysis, which revealed RR shifts from 0.73 (95% CI: 0.52-0.94) to 0.75 (95% CI: 0.63-1.01), found no significant influence of individual studies on the overall effect.

For the studies comparing G2 DES with PES, MI rates were 5.66% (243/4,291) for PES and 3.06% (172/5,614) for G2 DES, with a 40% RRR favouring G2 DES (RR=0.60, 95% CI: 0.49-0.72, $p\leq 0.001$).




Figure 4. Stratified analysis of patient-focused outcomes according to study design characteristics and length of dual antiplatelet therapy. The Figure shows relative risks for patient-focused outcomes in a stratified analysis of pooled clinical trials according to inferiority or non-inferiority/superiority design, length of follow-up, performance of angiographic follow-up, and length of dual antiplatelet therapy (DAPT). * denotes a p -value ≤ 0.05 . Boxes represent point estimates and lines 95% confidence intervals. G1 DES: first-generation drug-eluting stent; G2 DES: second-generation drug-eluting stent; ID-TLR: ischaemia-driven target lesion revascularisation; MI: myocardial infarction; RR: relative risk; ST: stent thrombosis




Figure 5. Myocardial infarction in first and second-generation drug-eluting stents. Forest plot illustrating relative risk of myocardial infarction with first versus second-generation drug-eluting stent. Filled squares represent relative risks; square areas are proportional to the weight of individual studies; diamonds represent pooled relative risks; horizontal lines represent 95% confidence intervals.

No significant heterogeneity was found in the studies comparing G2 with PES ($I^2=0\%$, $p_{\text{het}}=0.80$). Conversely, no significant difference in MI rate was found between SES (3.55%, 243/6,831) and G2 DES (2.91%, 215/7,387) (RR=0.91, 95% CI: 0.69-1.20, $p=0.85$). Adjusted indirect comparison analysis revealed a significant RRR of 32% with EES use when compared with SES (RR=0.68, 95% CI: 0.50-0.93, $p=0.01$) (Figure 3B).

DEATH

Figure 6 shows forest plots for the endpoint of death. Thirteen studies (14 comparisons) reported the incidence of death in 22,018 patients (10,176 G1 and 11,842 G2 DES). The NOBORI Japan trial, SPIRIT II, and SORT OUT IV were not included since the all death rate was not reported^{17,20,24}. No significant differences were found in death rates between G1 and G2 DES: 3.56% (363/10,176) in G1 and 3.79% (291/11,842) in G2 DES groups (RR=0.89, 95% CI: 0.74-1.05, $p=0.17$). No heterogeneity among studies was detected ($I^2=27\%$, $p_{\text{het}}=0.17$), and sensitivity analysis did not reveal significant changes in the overall effect with exclusion of individual studies (RR shift from 0.92 [95% CI: 0.73-1.10] to 1.04 [95%

CI: 0.82-1.23]). Only one trial showed a significant reduction of death risk with the use of G2 DES¹³ (Figure 7).

In the studies comparing PES with G2 DES, death rates were 2.82% (119/4,214) for PES and 2.42% (131/5,391) for G2 DES. This difference was non-significant (RR=0.83, 95% CI: 0.65-1.06, $p=0.14$). In studies comparing SES with G2 DES there were no significant differences: 3.23% (141/4,362) for SES and 3.31% (161/4,854) for G2 DES; the overall effect was comparable between both groups (RR=0.93, 95% CI: 0.66-1.32, $p=0.14$). As with previous endpoints, an adjusted indirect comparison analysis was performed to compare SES with EES, but non-significant RRR associated with EES use was found (RR=0.98, 95% CI: 0.82-1.18, $p=0.86$) (Figure 3C).

STENT THROMBOSIS

Figure 7 shows the forest plot for ST (definitive and probable stent thrombosis according to ARC criteria). The incidence of ST was reported in 16 studies (17 comparisons) involving a total of 25,427 patients. The overall prevalence of ST was 1.10% (282 events). There were no significant overall differences in ST prevalence in G1 and G2 DES: 1.35% (159/11,774) in the G1 DES and 0.90%




Figure 6. Death in first and second-generation drug-eluting stents. Forest plot illustrating the relative risk of all deaths with first versus second-generation drug-eluting stents. Filled squares represent relative risks; square areas are proportional to the weight of individual studies; diamonds represent pooled relative risks; horizontal lines represent 95% confidence intervals.




Figure 7. Stent thrombosis in first and second-generation drug-eluting stents. Forest plot illustrating the relative risk of stent thrombosis with first versus second-generation drug-eluting stents. Filled squares represent relative risks; square areas are proportional to the weight of individual studies; diamonds represent pooled relative risks; horizontal lines represent 95% confidence intervals.

(123 of 13,653) in the G2 DES (RR=0.69, 95% CI: 0.54-0.88, p=0.004). Per G1 DES comparator, ST rates were 1.84% and 1.07% for TAXUS and CYPHER, respectively.

Separate analysis of the studies comparing PES and G2 DES revealed a significant RRR (59%) associated with G2 DES use (RR=0.41, 95% CI: 0.26-0.65, p<0.01). The number of ST events prevented by using G2 DES in 1,000 patients was 4.2 (95% CI: 1.7-6.1) (NNT=239.7). On the contrary, no significant differences in ST were found in the comparison between SES and G2 DES (RR=0.92, 95% CI: 0.68-1.24, p=0.58). There was no evidence of significant heterogeneity among studies (I²=38%, p_{het}=0.12). Sensitivity analysis revealed an RR ranging from 0.69 (95% CI: 0.41-1.08) to 0.89 (95% CI: 0.57-1.38), showing no significant influence of individual studies on the overall effect.

SENSITIVITY ANALYSIS ACCORDING TO METHODOLOGICAL AND CLINICAL VARIABLES

We evaluated the consistency of our analyses by performing stratified analyses for ID-TLR, MI, death and ST by selected methodological and clinical variables (Figure 8). For ID-TLR and death, the overall treatment effect of G2 DES remained consistent for each variable using either

design, length of follow-up and clopidogrel duration. However, the ID-TLR treatment effect varied positively for G2 DES in trials with protocol angiographic follow-up (RR=0.82, 95% CI: 0.62-1.00, p=0.05). For MI, the overall benefit observed for G2 DES was consistent in all the variables explored. Nevertheless, regarding clopidogrel duration, the benefit was observed in those trials when the duration of dual antiplatelet therapy was extended until 12 months^{9,12,14,18,23,24}. A significantly lower relative risk of MI (RR=0.54, 95% CI: 0.51-0.86, p=0.002) was associated with the use of G2 DES with thin struts (<91 microns). No effect of erodible or non-erodible polymer was documented (Figure 8).

PUBLICATIONS BIAS

Visual inspection of funnel plots did not reveal asymmetry for the endpoints MI, death and ST. In support, the Begg's rank correlation and Egger's regression test were not statistically significant. Although some asymmetry was noted in the funnel plot for endpoint ID-TLR, the existence of publication bias for this endpoint was ruled out by the non-significant results of the Begg's rank correlation and Egger's regression test (p=0.84 and p=0.84, respectively). Similar results were obtained for MI, death and ST. Finally, the majority of studies were classified as low risk of bias across all domains of study quality (Table 1).




Figure 8. Stratified analysis of patient-focused outcomes according to stent strut thickness and type of eluting polymer. The Figure shows relative risks for patient-focused outcomes in a stratified analysis of pooled clinical trials according to stent strut thickness and type of eluting polymer. The pooled estimates are reported as relative risk. Boxes represent point estimates and lines 95% confidence intervals. ID-TLR: ischaemia-driven target lesion revascularisation; MI: myocardial infarction; RR: relative risk; ST: stent thrombosis

Discussion

The systematic review and trial level meta-analysis reveal that technological modifications introduced in G2 DES have translated into better patient outcomes than documented with G1 DES. Since the study revealed the existence of major sources of bias in the use of a G1 comparator, a separate analysis was performed for PES and SES as comparators. Overall, changes introduced in G2 DES technology have clearly increased the level of safety and efficacy reached with G1 DES. Although direct pooled analysis of available RCTs comparing G1 versus G2 DES did not show a clear clinical benefit in terms of ID-TLR risk reduction, a statistically significant rate of reduction of MI and stent thrombosis favouring G2 DES was documented in our analysis. Moreover, an indirect comparison of existing trials revealed a superiority of EES over SES in terms of ID-TLR. Importantly, the use of thinner stent struts was identified as a contributor to better outcome of G2 DES. In the following paragraphs these issues are discussed in detail.

The pace of developments in the field of percutaneous revascularisation implies an almost constant lag between evidence and use, or even availability, of tested devices. Most of the available evidence on the safety and efficacy of DES is based on the evidence gathered with the CYPHER and TAXUS DES in major trial programmes; however, they will soon be no longer available (TAXUS Liberté has been replaced by the thinner strut, platinum chromium alloy PES TAXUS Element, and the production of CYPHER Select

was discontinued by the end of 2011)^{25,26}. As a consequence of this, percutaneous revascularisation will be carried out using G2 DES that have been approved by regulatory authorities on the grounds of trials comparing G1 and G2 DES. Many of these trials followed a non-inferiority or sequential non-inferiority/superiority design for the primary outcome, which frequently was a composite endpoint. The aim of this study was to investigate whether the modifications introduced in the structural and antiproliferative components of G2 DES with the aims of improving safety and efficacy have translated to better patient-oriented outcomes. For this reason, combined endpoints were avoided, and individual outcomes (death, MI and ID-TLR) were used instead²⁷. Studies not reporting patient-oriented outcomes could not, therefore, be included in our analysis.

THE EFFECT OF G1 COMPARATOR ON ASSESSMENT OF G2 DES PERFORMANCE

Since the study revealed the existence of major sources of bias in the use of a G1 comparator, a separate analysis was performed for PES and SES as comparators, and major differences in the outcome of G2 DES when compared with the TAXUS or CYPHER G1 DES were found. The choice of a comparator constitutes one of the key issues in designing valid non-inferiority/equivalency trials²⁸. In spite of the fact that the TAXUS stent was introduced after the G1 CYPHER stent, much of the available evidence on G2 DES comparisons has been obtained in patients included in trials that used

TAXUS as a G1 comparator (41% of overall included patients). The preference for the use of the TAXUS stent as a comparator in non-inferiority trials was not specified in any study.

Regarding the G1 TAXUS stent, our analysis demonstrates that its efficacy and safety have been improved by the modifications made in G2 DES, as judged by the pooled analysis of comparative studies with EES, ZES and BES. A consistent improvement, supported by a lack of heterogeneity between studies, was observed in terms of reduction of ID-TLR, MI and stent thrombosis (**Figure 2**, **Figure 6** and **Figure 7**).

Although at first glance the results of our analysis do not suggest that G2 have improved outcome when compared with G1 Cypher, attention should be paid to the important bias in comparisons with G2 EES before drawing conclusions. Although direct pooled comparisons of the CYPHER stent versus G2 DES reveal no significant improvement regarding safety and efficacy, removing ZES comparison results (ENDEAVOR III, ISAR-TEST-2, SORT OUT III and ZEST [CYPHER]) from analysis revealed a statistically significant benefit in terms of ID-TLR and MI favouring G2 DES (RR=0.78, 95% CI: 0.65-0.92, $p=0.02$) and (RR=0.81, 95% CI: 0.73-0.98, $p=0.04$), respectively (data not included in forest plot). This finding implies that heterogeneities between different G2 DES should be taken into account in interpreting these results. On the other hand, RCTs comparing EES account for 68% of all patients (6,789/9,905) included in trials using TAXUS as a G1 comparator, but only for 45% (5,521/12,235) of patients included in RCTs with CYPHER as comparator. These differences in the selection of the G1 DES comparator could constitute a source of bias, and might potentially have influenced our analysis.

We also performed an indirect comparison between G2 EES versus G1 DES, based on the following reasons: 1) presence of conflicting results in individual trials comparing SES versus EES; 2) need to exclude several studies comparing SES and EES on the grounds that ischaemia-driven TLR, a primary efficacy endpoint in our meta-analysis, was not reported; and 3) need to provide as much evidence as possible on the effect of G2 DES on patient outcomes, compared with G1, in a research scenario that has prompted the use of PES as a comparator against G2 DES. Indirect comparison meta-analyses have recently been proposed and been shown to predict rather reliable results of subsequent direct randomised comparisons⁷.

The results of this indirect comparison suggest, compared to the CYPHER stent, a distinct benefit of G2 EES for the endpoints of ID-TLR and MI. Some of these results are supported by the LESSON-1 study, a historically controlled, non-randomised study comparing EES and SES²⁸. In LESSON-1, the decrease in MI associated with G2 EES (hazard ratio [HR] 0.62, $p=0.017$) was virtually identical to that estimated in our indirect comparison (RR 0.68, $p=0.01$), as well as the risk of death (HR 0.88 in LESSON-1 [$p=0.59$], RR 0.96 in our study [$p=0.92$]). Conversely, no significant differences in TLR in LESSON-1 (HR 0.80, $p=0.80$) were found between EES and SES, while in our indirect comparison a statistically borderline difference favouring EES was noted (RR 0.76, $p=0.05$). It is not possible to infer from our trial-level meta-

analysis whether differences in TLR were related to stent thrombosis. In LESSON-1, differences in target vessel revascularisation (TVR) between SES and EES were partially related to a lower prevalence of ST in EES-treated patients²⁸.

INFLUENCE OF THE DESIGN OF RCTS

By combining data from multiple trials in a meta-analysis we sought to overcome the limitations of non-inferiority margin election and other methodological problems that have been attributed to non-inferiority designs²⁸. We also performed a separate sensitivity analysis to investigate whether the conclusions of RCTs with a non-inferiority design were different from those with non-inferiority/superiority design, without finding significant differences.

Conversely, in the RCTs with angiographic follow-up no significant advantage of G2 DES over G1 DES could be demonstrated regarding the endpoint of ID-TLR. The G1 comparators in trials with angiographic follow-up were the TAXUS stent in four RCTs^{9,16,20,21} and the CYPHER stent in eight RCTs^{9-11,13-15,17,18}. The former finding can be explained by the well-known increase in TLR triggered by angiographic follow-up²⁹.

INFLUENCE OF STRUCTURAL CHARACTERISTICS OF DES

We also investigated the impact on patient outcome of specific changes introduced in G2 stent platforms to improve stent haemorrhology and biocompatibility, such as decreased strut thickness and biodegradable eluting matrices.

Stratified analysis of pooled RCTs revealed that the use of thin-strut DES design is associated with a significant reduction of MI. Again, a bias in G1 comparator was noted in the use of thin-strut G2 DES. Cobalt-chromium G2 DES with $<0.91\ \mu\text{m}$ strut thickness were used in 68% (6,789/9,905) of patients included in RCTs with PES as comparator, but only in 45% (5,521/12,235) of those comparing G2 and SES, that was more frequently compared with stainless steel 119 μm thick-strut DES (Nobori and Biomatrix) than the TAXUS stent. Thus, the preponderance of thin-strut G2 DES in comparisons with PES may also have contributed to the significantly higher reduction of MI observed in G2 in those trials. The finding that DES strut thickness influences outcome is supported by previous studies reporting a proportional relationship between stent strut thickness and thrombogenicity³⁰, strut malapposition³¹, and decreased neointimal coverage³². Overlapping of DES, which is frequently required to treat tapered, long or bifurcation stenoses, has been identified in clinical series as a predictor of MI³³. At these overlapping locations, haemodynamic phenomena, increased flow separation, stagnation and reattachment are magnified by strut thickness³⁴.

Non-erodible polymer matrices have been proposed as a cause of persistent inflammatory vascular reactions which might be causative in long-term appearing stent malapposition, incomplete strut coverage and stent thrombosis³⁵. Three of the trials included in our analysis tested a G2 DES with a polylactic acid biodegradable-eluting matrix in a relatively small number of patients (10% of G2 DES, 1,208/12,056), more frequently against a PES G1 comparator (87%, 1,055/1,208). No significant advantage of this particular feature

could be detected in the sensitivity analysis performed. A recent study by Navarese et al which focused on this topic also failed to detect significant advantages in target lesion revascularisation, MI and death, of biodegradable polymer DES compared with non-erodible polymer designs³⁶.

INFLUENCE OF G2 DES TECHNOLOGY ON STENT THROMBOSIS

Our analysis revealed a statistically significant reduction in the risk of stent thrombosis associated with the use of G2 DES (RR=0.69, 95% CI: 0.54-0.88, p=0.004). Moreover, a *post hoc* trial analysis including studies reporting very late ST rates showed a statistically significant benefit of G2 DES (0.96%; 47/4,873) over G1 DES (1.72%; 71/4,115), (RR=0.62, 95% CI: 0.42-0.92, p=0.02)^{10-14,16-20}. Although this finding could be influenced by comparisons of G2 DES versus PES, some changes introduced into newer design features in G2 DES may account for these results. For instance, flow disturbances caused by strut thickness may affect endothelialisation which is minimised by G2 DES improvements³⁷. Likewise, drug concentration changes introduced in G2 DES may potentially reduce the toxicity and local inflammation, which both improve healing³⁸. Finally, the use of erodible polymers in newer DES has been recognised as an important contributor to lower ST risk. This was proven by a recent meta-analysis comparing the safety and efficacy of biodegradable versus durable polymer DES which showed a significant reduction of late/very late ST rate (RR=0.60, 95% CI: 0.39-0.91, p=0.02)³⁶.

Limitations

There are additional limitations of our study to those mentioned in the above discussion. Our meta-analysis was not performed at a patient level, and therefore the effect of study population characteristics could not be addressed. Although in most analyses no statistically significant heterogeneity was detected, it is quite clear that other sources of heterogeneity among studies exist, including clinical settings, stent platforms and eluting polymers. Relevant issues such as drug-elution kinetics could not be addressed. Intracoronary guidance of DES implantation was not included as part of the study protocol in any of the trials. Assessment of ST was hampered by the lack of: 1) details on when ST occurred (cumulative incidence of ST could not therefore be calculated); and 2) data on clopidogrel adherence.

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

1. Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, Tanaka N, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura K, Asakura Y, Suzuki T. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. *EuroIntervention*. 2010;5:841-6.
2. Martín-Reyes R, Moreno R, Sánchez-Recalde A, Navarro F, Franco J, Piñero A, Sendón JL. Comparison of the safety between first- and second-generation drug eluting stents: meta-analysis from 19 randomized trials and 16,924 patients. *Int J Cardiol*. 2012;160:181-6.

3. Jensen LO, Tilsted HH, Thayssen P, Kaltoft A, Maeng M, Lassen JF, Hansen KN, Madsen M, Ravkilde J, Johnsen SP, Sørensen HT, Thuesen L. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. *EuroIntervention*. 2010;5:898-905.

4. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008 www.cochrane-handbook.org 2007 Accessed September 1, 2009.

5. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. *Lancet*. 1999;354:1896-900.

6. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;115:2344-51.

7. Bucher HC, Guyatt GH, Griffith LE, Walter DS. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol*. 1997;50:683-91.

8. Schomig A, Dibra A, Windecker S, Mehili J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. *J Am Coll Cardiol*. 2007;50:1373-80.

9. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Hong TJ, Park HS, Park SJ. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. *J Am Coll Cardiol*. 2010;56:1187-95.

10. Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schömig A, Mehili J; ISAR-TEST-2 Investigators. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor drug-eluting stents (ISAR-TEST-2). *J Am Coll Cardiol*. 2010;55:2536-43.

11. Byrne RA, Kastrati A, Massberg S, Wiecek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehili J; ISAR-TEST 4 Investigators. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. *J Am Coll Cardiol*. 2011;58:1325-31.

12. Smits PC, Kedhi E, Roayaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents

for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). *J Am Coll Cardiol.* 2011;58:11-8.

13. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). *JACC Cardiovasc Interv.* 2011;4:543-50.

14. Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. *JACC Cardiovasc Interv.* 2010;3:1043-50.

15. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. *J Am Coll Cardiol.* 2011;58:1844-54.

16. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. *Circ Cardiovasc Interv.* 2009;2:188-95.

17. Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, Nanto S, Fujii K, Inoue N, Namiki A, Kimura T, Mitsudo K. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. *Catheter Cardiovasc Interv.* 2012;80:789-96.

18. Stefanini G, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of bio-degradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. *Lancet.* 2011;378:1940-8.

19. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H, Kimura K, Simonton CA, Kozuma K; RESET Investigators. Comparison of everolimus-eluting and sirolimus-eluting

coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). *Circulation.* 2012;126:1225-36.

20. Garg S, Serruys PW, Miquel-Hebert K. Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial. *Catheter Cardiovasc Interv.* 2011;77:1012-7.

21. Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat F, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). *Am J Cardiol.* 2011;107:833-40.

22. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ. Randomized comparison of everolimus- and paclitaxel-eluting stents 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial. *J Am Coll Cardiol.* 2011;58:19-25.

23. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrøm T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrøm SZ, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Johnsen SP, Jensen LO, Sørensen HT, Thuesen L, Lassen JF; SORT OUT III study group. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. *Lancet.* 2010;375:1090-9.

24. Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, Villadsen AB, Junker A, Hansen KN, Kaltoft A, Maeng M, Pedersen KE, Kristensen SD, Bøtker HE, Ravkilde J, Sanchez R, Aarøe J, Madsen M, Sørensen HT, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). *Circulation.* 2012;125:1246-55.

25. Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, Dauber IM, Rabinowitz AC, Ball MW, Bertolo B, Kabour A, Foster MC, Wang JC, Underwood P, Dawkins KD. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. *J Am Coll Cardiol.* 2010;56:264-71.

26. Cordis to Stop Making Cypher, Nevo Stents. Available at <http://www.medpagetoday.com/ProductAlert/DevicesandVaccines/27086>. Accessed at May 28, 2012.

27. Kip K, Hollabaugh K, Marroquin O, Williams D. The problem with composite end points in cardiovascular studies. *J Am Coll Cardiol.* 2008;51:701-7.

28. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann Intern Med.* 2006;145:62-9.

29. Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, Muramatsu T, Nakamura M, Nanto S, Yokoi H, Baim DS. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of “oculostenotic” reintervention in patients with intermediate lesions. *JACC Cardiovasc Interv.* 2010;3:403-11.
30. Räber L, Jüni P, Löffel L, Wandel S, Cook S, Wenaweser P, Togni M, Vogel R, Seiler C. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. *J Am Coll Cardiol.* 2010;55:1178-88.
31. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. *Circulation.* 2011;123:1400-9.
32. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. *Int J Cardiol.* 2009;134:180-8.
33. Pache J, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Müller M, Dirschinger J, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STereo-2) trial. *J Am Coll Cardiol.* 2003;41:1283-8.
34. Räber L, Jüni P, Löffel L, Wandel S, Cook S, Wenaweser P, Togni M, Vogel R, Seiler C, Eberli F, Lüscher T, Meier B, Windecker S. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. *J Am Coll Cardiol.* 2010;55:1178-88.
35. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, Christians U, Betts R, Savage D, Su SH, Schulze J, Kar S. Polymer-free Biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. *Circ Cardiovasc Interv.* 2010;3:174-83.
36. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. *EuroIntervention.* 2011;7:985-94.
37. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skoriya K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. *J Am Coll Cardiol.* 2008;52:333-42.
38. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. *Circulation.* 2007;115:2435-41.